Windtree Therapeutics Enters Material Definitive Agreement

TL;DR

**Windtree Therapeutics signed a big deal, but they're not telling us what it is yet.**

AI Summary

Windtree Therapeutics, Inc. filed an 8-K on January 17, 2024, to report an "Entry into a Material Definitive Agreement" that occurred on January 12, 2024. While the filing confirms a significant agreement was made, it does not disclose the specific details of the agreement itself. This matters to investors because material agreements can significantly impact a company's future operations, financial health, and stock value, but without the specifics, the impact remains unknown.

Why It Matters

This filing signals a potentially significant business development for Windtree Therapeutics, Inc., but the lack of specific details means investors are left in the dark about its nature and potential impact.

Risk Assessment

Risk Level: medium — The risk is medium because a material agreement has been made, which could be positive or negative, but the absence of details creates uncertainty for investors.

Analyst Insight

A smart investor would monitor Windtree Therapeutics for subsequent filings or press releases that provide details about this material definitive agreement before making any investment decisions, as the current filing lacks actionable information.

Key Numbers

• $0.001 — Par Value per Share (The par value of Windtree Therapeutics' Common Stock.)

Key Players & Entities

• Windtree Therapeutics, Inc. (company) — the registrant filing the 8-K
• January 12, 2024 (date) — date of the earliest event reported (entry into material definitive agreement)
• January 17, 2024 (date) — date the 8-K was filed
• $0.001 (dollar_amount) — par value per share of common stock

Forward-Looking Statements

• Windtree Therapeutics will file another 8-K or press release within the next 30-60 days to disclose the details of this material definitive agreement. (Windtree Therapeutics, Inc.) — medium confidence, target: 2024-03-17

FAQ

Key Financial Figures

• $0.001 — h registered Common Stock , par value $0.001 per share   WINT   The
• $3.1 million — greement, the Company may receive up to $3.1 million in potential upfront pre-development, d
• $135.25 million — regulatory milestone payments and up to $135.25 million in sales milestone payments. The Compan
• $100,000 b — t, the Company agreed to pay PM USA (1) $100,000 by January 18, 2024, (2) $400,000 no late
• $400,000 — A (1) $100,000 by January 18, 2024, (2) $400,000 no later than the earlier of (a) July 1
• $1.4 million — 17, 2024 and (3) up to an aggregate of $1.4 million upon the achievement of certain develop
• $75,000 b — nt, the Company agreed to pay PMPSA (1) $75,000 by January 19, 2024 (the " Upfront Paymen
• $325,000 — 19, 2024 (the " Upfront Payment "), (2) $325,000 no later than the earlier of (a) July 1

Filing Documents

• wint20240116_8k.htm (8-K) — 37KB
• 0001437749-24-001469.txt ( ) — 169KB
• wint-20240112.xsd (EX-101.SCH) — 3KB
• wint-20240112_def.xml (EX-101.DEF) — 11KB
• wint-20240112_lab.xml (EX-101.LAB) — 15KB
• wint-20240112_pre.xml (EX-101.PRE) — 11KB
• wint20240116_8k_htm.xml (XML) — 3KB

01           Entry into a Material Definitive Agreement

Item 1.01           Entry into a Material Definitive Agreement.   License Agreement with Lee ' s Pharmaceutical (HK) Ltd.   On January 12, 2024 Windtree Therapeutics, Inc. (the " Company ") entered into a License, Development and Commercialization Agreement with Lee's Pharmaceutical (HK) Ltd., a company organized under the laws of Hong Kong (" Lee ' s "), effective as of January 7, 2023 (the " Lee ' s License Agreement ").   Under the Lee's License Agreement, the Company granted to Lee's an exclusive license, with a right to sublicense, to develop, register, make, use, sell, offer for sale, import, distribute and otherwise commercialize products that incorporate istaroxime for intravenous administration, rostafuroxin for oral administration, and the Company's proprietary dual-mechanism SERCA2a activators for intravenous or oral administration (collectively, the " Products " and each, a " Product "), in each case for the prevention, mitigation and/or treatment of any disease, disorder or condition in humans including acute decompensated heart failure, cardiogenic shock, and chronic use following discharge of an individual hospitalized for acute decompensated heart failure (" Field ") in the People's Republic of China, Hong Kong, Macau, Taiwan, Singapore, South Korea, Thailand, Vietnam, Brunei, Myanmar, Cambodia, East Timor, Indonesia, Laos, Malaysia, and the Philippines (the " Licensed Territory ").   Under the Lee's License Agreement, the Company may receive up to $3.1 million in potential upfront pre-development, development, clinical, and regulatory milestone payments and up to $135.25 million in sales milestone payments. The Company is also entitled to receive a low double-digit percentage of Lee's non-royalty sublicense income.   The Company is eligible to receive tiered royalties based on a percentage of Net Sales (as defined in the Lee's License Agreement) that ranges from low si

SIGNATURES

SIGNATURES   Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.   Date: January 17, 2024 Windtree Therapeutics, Inc.             By: /s/ Craig E. Fraser     Name: Craig E. Fraser     Title: President and Chief Executive Officer          

View Full Filing

View this 8-K filing on SEC EDGAR